Search Resources (English): Health protection, Women and Health Protection (WHP)

Examines the results of the Women's Health Initiative (WHI) study regarding hormone replacement therapy.

 (See Details)

Examines the question of harmonisation of pharmaceutical regulation and its implications for women and public health. Urges that safety standards be paramount and the particular needs of women and other groups are not lost.

 (See Details)

Presents cautions to regulators, consumers, practitioners, and researchers to learn from the past in order to protect women’s health in the future.

 (See Details)

Examines the Canadian system of adverse drug reactions reporting and that women’s particular susceptibilities to drug-related health risks must be taken into consideration.

 (See Details)

Examines the effects of direct-to-consumer advertising (DTCA) of pharmaceuticals.

 (See Details)

Criticizes federal prescription drug regulation using Diane-35 (cyproterone acetate and ethinyl estradiol) as an example.

 (See Details)

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

 (See Details)

Argues that the lack of transparency in the drug approval process can lead to inappropriate, unnecessary and sometimes dangerous drug use, and it impedes the development of knowledge and appropriate decision-making.

 (See Details)

Argues that the federal government is protecting drug companies instead of the public by keeping information about the drug approval process secret. Examines the impact of this on women's health. (See Details)

Presents the proceedings of a symposium that examined women and the pharmaceuticals industry. Includes presentations of the three panellists and a brief summary of each of the workshops. (See Details)